Resmed Inc. Aktie
186,80 €
Deine Einschätzung
Resmed Inc. Aktie
Was spricht für und gegen Resmed Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Resmed Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Resmed Inc. | 0,88 % | -0,56 % | -2,73 % | -5,51 % | 19,17 % | -13,64 % | 67,93 % |
Boston Scientific | 2,16 % | 0,00 % | -2,05 % | 49,61 % | 39,00 % | 93,56 % | 90,06 % |
Illumina Inc. | -1,64 % | -1,11 % | 3,66 % | -38,55 % | -18,10 % | -74,17 % | -59,54 % |
Thermo Fisher Scientific Inc. | -0,89 % | -2,31 % | -7,02 % | -2,81 % | 1,91 % | 12,66 % | 88,92 % |
Kommentare
News
![How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?: https://g.foolcdn.com/editorial/images/782157/mfm_24.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN0hKYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f0170a3f195c0995fc2a7f890e1295405b87310b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/mfm_24.jpg?locale=de)
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?
ResMed has had the market on sleep apnea cornered for a while, but new weight loss drugs might be creeping in. In this podcast, we look at what could change based on recent studies and some other
![Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market: https://www.marketbeat.com/logos/articles/med_20240630174256_charty-lly.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXJJYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1ac61e5394abb0f95cf1314afe9071803f9c5d14/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240630174256_charty-lly.jpg?locale=de)
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is
![Why ResMed Stock Is Soaring Today: https://g.foolcdn.com/editorial/images/774544/cpap-mask-person.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOVdDYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d2cdb54b7994de106eb3c0ec9b59ef4806301fa2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/cpap-mask-person.jpg?locale=de)
Why ResMed Stock Is Soaring Today
Shares of ResMed (NYSE: RMD) had soared 16.2% higher as of 11:50 a.m. ET on Friday. The big jump came after the healthcare technology company reported results on Thursday evening for its fiscal 2024